蒋 晨,谢小东,万新娟,丁 琳,刘 琪.格列喹酮联合复方樟柳碱治疗糖尿病性视乳头炎临床疗效探究[J].,2021,(10):1883-1888 |
格列喹酮联合复方樟柳碱治疗糖尿病性视乳头炎临床疗效探究 |
Clinical Effect of Gliquidone Combined with Compound Anisodine on Diabetic Papillitis |
投稿时间:2020-08-03 修订日期:2020-08-26 |
DOI:10.13241/j.cnki.pmb.2021.10.017 |
中文关键词: 格列喹酮 复方樟柳碱 糖尿病性视乳头炎 临床疗效 |
英文关键词: Gliquidone Compound anisodine Diabetic optic papillitis Clinical efficacy |
基金项目:新疆维吾尔自治区自然科学基金项目(2017D01C118) |
|
摘要点击次数: 815 |
全文下载次数: 446 |
中文摘要: |
摘要 目的:探究格列喹酮联合复方樟柳碱在治疗糖尿病性乳头炎中的临床效果。方法:选择2019年6月至2020年1月于我院接受治疗的100例糖尿病性视乳头炎患者,按照其选择治疗方式的差异将其分为实验组与对照组(每组50例),对照组患者仅接受复方樟柳碱治疗,实验组患者在对照组基础上加用格列喹酮治疗,对比两组患者治疗效果、治疗前后视力水平、视野平均缺损程度、脂联素水平、超敏-C反应蛋白(hypersensitive C-reactive protein,hs-CRP)水平、血管内皮生长因子(vascular endothelial growth factor ,VEGF)水平、不良情绪及生活质量的变化,对比治疗中不良反应发生率。结果:(1)实验组总有效率98.00 %,对照组总有效率86.00 %,两组比较差异明显(P<0.05);(2)治疗前两组患者视力水平和视野平均缺损程度差异不大,治疗后两组患者视力水平明显提升,视野平均缺损程度明显下降,同时实验组视力水平高于对照组,视野平均缺损程度低于对照组(P<0.05);(3)治疗前两组患者的脂联素、hs-CRP以及VEGF水平无差异(P>0.05),治疗后实验组脂联素水平高于对照组,hs-CRP和VEGF水平低于对照组(P<0.05);(4)治疗前两组HAMA、HAMD和SF-36评分无差异(P>0.05),治疗后实验组HAMA和HAMD评分低于对照组(P<0.05),SF-36高于对照组(P<0.05);(5)实验组不良反应总发生率12.00 %,对照组为10.00 %,两组对比无差异(P>0.05)。结论:格列喹酮联合复方樟柳碱对糖尿病性视乳头炎具有较好的治疗效果,能够显著降低患者视野缺损程度,提高患者视力水平,降低患者炎症介质和血管生长因子水平,缓解患者的焦虑抑郁情绪,改善患者的生活质量,同时治疗的安全性还较高,值得临床推广应用。 |
英文摘要: |
ABSTRACT Objective: To explore the clinical effect of gliquidone combined with compound anisodine in the treatment of diabetic papillitis. Methods: A total of 100 patients with diabetic papillitis,who were treated in People's Hospital of Xinjiang Uygur Autonomous Region from June 2019 to January 2020, were divided into experimental group and control group (50 cases in each group). The patients in the control group were given compound anisodine only, and the patients in the experimental group were treated with gliquidone on the basis of the control group's therapy. The treatment effect, vision level, average visual field defect degree, adiponectin level, hs-CRP level, vascular endothelial growth factor (VEGF) level, adverse mood and quality of life of the two groups were compared before and after treatment, and the incidence of adverse reactions during treatment was compared. Results: (1) The total effective rate was 98.00 % in the experimental group and 86.00 % in the control group, with significant difference between the two groups (P<0.05). (2) Before treatment, there was no significant difference in visual acuity and visual field average defect degree between the two groups, but after treatment, the visual acuity of the two groups was significantly improved, while the visual field average defect degree of the experimental group was higher than that of the control group (P<0.05). (3) Before treatment, the levels of adiponectin, hs-CRP and VEGF in the two groups were not significantly different (P>0.05), but after treatment, the levels of adiponectin in the experimental group were higher than those in the control group,but hs-CRP and VEGF in the experimental group were lower than those in the control group (P<0.05). (4) Before treatment, the scores of HAMA, HAMD and SF-36 in the two groups were not significantly different (P>0.05), while the scores of HAMA and HAMD in the experimental group were lower than those in the control group (P<0.05), and SF-36 was higher than that in the control group (P<0.05). (5) The total incidence of adverse reactions was 12.00 % in the experimental group and 10.00% in the control group, with little difference between the two groups (P>0.05). Conclusion: Gliquidone combined with compound anisodine has a good therapeutic effect on diabetic papillitis.It can significantly reduce the degree of visual field defect, improve patients' visual acuity, reduce the levels of inflammatory mediators and vascular growth factors, relieve patients' anxiety and depression, and improve patients' quality of life. At the same time, the treatment is safe and worthy of clinical application. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|